{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T21:50:25Z","timestamp":1775339425953,"version":"3.50.1"},"reference-count":40,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1248\/bpb.b21-00230","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:08:46Z","timestamp":1630447726000},"page":"1294-1302","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data"],"prefix":"10.1248","volume":"44","author":[{"given":"Aya","family":"Enomoto","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Mano","sequence":"additional","affiliation":[{"name":"Department of Clinical Drug Informatics, Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Drug Informatics, Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. <i>Stroke<\/i>, <b>22<\/b>, 983\u2013988 (1991).","DOI":"10.1161\/01.STR.22.8.983"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. <i>Ann. Med.<\/i>, <b>39<\/b>, 371\u2013391 (2007).","DOI":"10.1080\/07853890701320662"},{"key":"3","unstructured":"3) Roger VL, Go AS, Lloyd-Jones DM, <i>et al.<\/i> Heart disease and stroke statistics\u20142012 update: a report from the American Heart Association. <i>Circulation<\/i> (New York, N.Y.), <b>125<\/b>, e2\u2013e220 (2012)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D\u2019Agostino RB. Stroke severity in atrial fibrillation. the Framingham study. <i>Stroke<\/i>, <b>27<\/b>, 1760\u20131764 (1996).","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"5","unstructured":"5) Granger CB, Alexander JH, McMurray JJV, <i>et al.<\/i> Apixaban <i>versus<\/i> warfarin in patients with atrial fibrillation. <i>N. Engl. J. Med.<\/i>, <b>365<\/b>, 981\u2013992 (2011)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Giugliano RP, Ruff CT, Braunwald E, <i>et al.<\/i> Edoxaban <i>versus<\/i> warfarin in patients with atrial fibrillation. <i>N. Engl. J. Med.<\/i>, <b>369<\/b>, 2093\u20132104 (2013).","DOI":"10.1056\/NEJMoa1310907"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM. Rivaroxaban <i>versus<\/i> warfarin in nonvalvular atrial fibrillation. <i>N. Engl. J. Med.<\/i>, <b>365<\/b>, 883\u2013891 (2011).","DOI":"10.1056\/NEJMoa1009638"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H, Joyner CD, Wallentin L. Dabigatran <i>versus<\/i> warfarin in patients with atrial fibrillation. <i>N. Engl. J. Med.<\/i>, <b>361<\/b>, 1139\u20131151 (2009).","DOI":"10.1056\/NEJMoa0905561"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. <i>Lancet<\/i>, <b>383<\/b>, 955\u2013962 (2014).","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. <i>Heart Rhythm<\/i>, <b>16<\/b>, e66\u2013e93 (2019).","DOI":"10.1016\/j.hrthm.2019.01.024"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Wang KL, Lip G, Lin S, Chiang C. Non\u2013Vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. <i>Stroke<\/i>, <b>46<\/b>, 2555\u20132561 (2015).","DOI":"10.1161\/STROKEAHA.115.009947"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. <i>Am. J. Cardiol.<\/i>, <b>120<\/b>, 1813\u20131819 (2017).","DOI":"10.1016\/j.amjcard.2017.07.092"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. <i>Chest<\/i>, <b>150<\/b>, 1302\u20131312 (2016).","DOI":"10.1016\/j.chest.2016.07.013"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Adeboyeje G, Sylwestrzak G, Barron JJ, White J, Rosenberg A, Abarca J, Crawford G, Redberg R. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. <i>J. Manag. Care Spec. Pharm.<\/i>, <b>23<\/b>, 968\u2013978 (2017).","DOI":"10.18553\/jmcp.2017.23.9.968"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M, Fosb\u00f8l EL, Torp-Pedersen C, Gislason GH, Olesen JB. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. <i>J. Intern. Med.<\/i>, <b>283<\/b>, 45\u201355 (2018).","DOI":"10.1111\/joim.12683"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. <i>Stroke<\/i>, <b>49<\/b>, 2933\u20132944 (2018).","DOI":"10.1161\/STROKEAHA.118.020232"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. <i>Thromb. Haemost.<\/i>, <b>116<\/b>, 975\u2013986 (2016).","DOI":"10.1160\/TH16-05-0403"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lamberts M, Staerk L, Olesen JB, Fosb\u00f8l EL, Hansen ML, Harboe L, Lefevre C, Evans D, Gislason GH. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: Contemporary findings in real-life Danish patients. <i>J.  Am. Heart Assoc.<\/i>, <b>6<\/b>, e004517 (2017).","DOI":"10.1161\/JAHA.116.004517"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the U.S. medicare population. <i>J. Manag. Care Speci.Pharm.<\/i>, <b>24<\/b>, 911\u2013920 (2018).","DOI":"10.18553\/jmcp.2018.24.9.911"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. department of defense population. <i>J. Manag. Care Speci. Pharm.<\/i>, <b>24<\/b>, 1116\u20131127 (2018).","DOI":"10.18553\/jmcp.2018.17488"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovi\u0107 J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis. <i>BMJ<\/i>, <b>359<\/b>, j5058 (2017).","DOI":"10.1136\/bmj.j5058"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Chan YH, Lee HF, See LH, Tu H, Chao T, Yeh Y, Wu L, Kuo C, Chang S, Lip GYH. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. <i>Chest<\/i>, <b>156<\/b>, 529\u2013543 (2019).","DOI":"10.1016\/j.chest.2019.04.108"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Mueller T, Alvarez-madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. <i>Br. J. Clin. Pharmacol.<\/i>, <b>85<\/b>, 422\u2013431 (2019).","DOI":"10.1111\/bcp.13814"},{"key":"24","unstructured":"24) XARELTO [package insert] 2011. Janssen Pharmaceuticals, Inc.; Titusville, NJ."},{"key":"25","unstructured":"25) PRADAXA [package insert] 2010. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT."},{"key":"26","unstructured":"26) \u201cFeatures of JMDC Claims Database\u201d: \u2039https:\/\/www.jmdc.co.jp\/pharma\/database.html\u203a, accessed 14 March, 2021."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. <i>Med. Care<\/i>, <b>43<\/b>, 1130\u20131139 (2005).","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. <i>Am. J. Epidemiol.<\/i>, <b>173<\/b>, 676\u2013682 (2011).","DOI":"10.1093\/aje\/kwq433"},{"key":"29","unstructured":"29) \u201cJCS\/JHRS Guideline on pharmacotherapy of cardiac arrhythmias. (2020 edition)\u201d: \u2039https:\/\/www.j-circ.or.jp\/old\/guideline\/pdf\/JCS2020_Ono.pdf\u203a, accessed 12 June, 2021."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hamatani Y, Ogawa H, Takabayashi K, Yamashita Y, Takagi D, Esato M, Chun Y, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. <i>Sci. Rep.<\/i>, <b>6<\/b>, 31042 (2016).","DOI":"10.1038\/srep31042"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Suzuki S, Yamashita T, Okumura K, Atarashi H, Akao M, Ogawa H, Inoue H. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy\u2014pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. <i>Circ. J.<\/i>, <b>79<\/b>, 432\u2013438 (2015).","DOI":"10.1253\/circj.CJ-14-1131"},{"key":"32","unstructured":"32) Kodani E, Atarashi H, Inoue H, <i>et al.<\/i> Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM registry. <i>J. Am. Heart Assoc.<\/i>, <b>5<\/b>, e004075 (2016)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CA, Maxwell BD, Chen S, He K, Goosen TC, Humphreys WG, Grossman SJ. <i>In vitro<\/i> assessment of metabolic drug\u2013drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. <i>Drug Metab. Dispos.<\/i>, <b>38<\/b>, 448\u2013458 (2010).","DOI":"10.1124\/dmd.109.029694"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Ohno S, Horie M, Terada T, Katsura T. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. <i>Br. J. Clin. Pharmacol.<\/i>, <b>84<\/b>, 1301\u20131312 (2018).","DOI":"10.1111\/bcp.13561"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Horie M, Terada T, Katsura T. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. <i>Pharmacogenet. Genomics<\/i>, <b>27<\/b>, 329\u2013336 (2017).","DOI":"10.1097\/FPC.0000000000000294"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>58<\/b>, 417\u2013421 (2002).","DOI":"10.1007\/s00228-002-0499-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Saeki M, Saito Y, Nakamura T, Murayama N, Kim S, Ozawa S, Komamura K, Ueno K, Kamakura S, Nakajima T, Saito H, Kitamura Y, Kamatani N, Sawada J. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. <i>Hum. Mutat.<\/i>, <b>21<\/b>, 653 (2003).","DOI":"10.1002\/humu.9147"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Hira D, Terada T. BCRP\/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. <i>Biochem. Pharmacol.<\/i>, <b>147<\/b>, 201\u2013210 (2018).","DOI":"10.1016\/j.bcp.2017.10.004"},{"key":"39","unstructured":"39) Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. <i>J. Am. Coll. Cardiol.<\/i>, <b>57<\/b>, 173\u2013180 (2011)."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, See LC, Kuo CF. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA<\/i>, <b>318<\/b>, 1250\u20131259 (2017).","DOI":"10.1001\/jama.2017.13883"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00230\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T04:19:35Z","timestamp":1630729175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00230\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00230","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"b21-00230"}}